Conivaptan is approved by the United States Food and Drug Administration (FDA) for hypervolemic (nephrotic syndrome, cardiac failure and cirrhosis) or
euvolemic hyponatremia (SIADH) treatment in adults, but not in children (10).
Dose comparison of conivaptan (Vaprisol[R]) in patients with
euvolemic or hypervolemic hyponatremia-efficacy, safety, and pharmacokinetics.
Euvolemic: Those patients who had no signs mentioned above were considered to be
euvolemic.
In a 2010 study of ICU patients, urea was used to treat
euvolemic hyponatremia and was found a safe, inexpensive, and simple.
The question arises whether it is possible to infuse fluids to a continuously
euvolemic patient (i.e.
Effects of saline infusion on hematologic parameters in
euvolemic subjects.
Based on history and clinical examination patients were classified as hypovolemic hyponatremia, hypervolemic hyponatremia and
euvolemic hyponatremia.
Of the 25 patients at baseline, 21 were clinically
euvolemic. Twelve of 15 patients who had a follow-up ASFM and SGA were clinically
euvolemic.
Both are indicated for
euvolemic and hypervolemic HN.
Cardiology evaluated the patient and recommended medical optimization and diuresis with plans for eventual right and left heart catheterization once he was
euvolemic. Gastroenterology evaluated the patient for his abdominal pain, nausea, vomiting, and elevated LFTs.
Clinical examination indicated
euvolemic fluid status.